跳至主要内容
临床试验/DRKS00033433
DRKS00033433招募中未知

Impact of nutritional supplementation of Bacillus megaterium DSM 32963 and an omega-3-polyunsaturated-fatty-acid-lysin complex in Ulcerative Colitis, a double-blind, placebo-controlled pilot proof-of-concept study - resIBD

Evonik Operations GmbH0 个研究点目标入组 24 人开始时间: 2024年1月24日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • patients with
  • -established mild/moderate ulcerative colitis (grade 2/3) in treatment with 5ASA (mesalazine) and not currently or previously treated with biologic agents or steroids
  • -who accept to undergo the study after informed consent
  • -if woman in childbearing age, adequate contraception in place
  • -Concomitant treatments, such as treatment for blood pressure, osteoporosis, and iron / vitamin supplements are only permitted if the therapy is stable and will likely not be discontinued during the study.

排除标准

  • -pregnancy
  • -any concomitant chronic disease or condition requiring steroids or NSAIDs therapy
  • -severe disease activity
  • -unable to give informed consent.

研究者

相似试验